SLC16A1 and cancer: These include the monocarboxylate transporter 1 (MCT1) inhibitors AZD3965 and AR-C155858 [4,5,6,7], the WEE1 inhibitor AZD1775 [8,9], the anaplastic lymphoma kinase (ALK) inhibitors AZD3463 and AZD5363 [10,11,12,13], the DNA-dependent protein kinase (DNA-PK) inhibitor AZD7648 [14,15,16], and other AZD-related inhibitors [17,18] employed in cancer treatment (Figure 1).